Similar articles for PMID: 32358086

Year	Number of Results
2015	2
2016	12
2017	16
2018	17
2019	26
2020	31
2021	41
2022	83
2023	61
2024	0

1

¹⁷⁷Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer.

Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X. Zang J, et al. J Nucl Med. 2020 Dec;61(12):1772-1778. doi: 10.2967/jnumed.120.242263. Epub 2020 May 1. J Nucl Med. 2020. PMID: 32358086 Free PMC article. Clinical Trial.

2

First-in-human study of ¹⁷⁷Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z, Chen X. Zang J, et al. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8. Eur J Nucl Med Mol Imaging. 2019. PMID: 30090965 Free PMC article.

3

A Single-Arm, Low-Dose, Prospective Study of ¹⁷⁷Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, Fan X, Zhang J, Zhu Z, Chen X. Wang G, et al. J Nucl Med. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3. J Nucl Med. 2023. PMID: 36328486 Free article.

4

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Heck MM, et al. Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30473431

5

Examining Absorbed Doses of Indigenously Developed ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.

Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5. Cancer Biother Radiopharm. 2021. PMID: 32379495

6

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.

7

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.

8

Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.

9

Radiation Dosimetry for ¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Okamoto S, et al. J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660138 Free article.

10

Clinical Outcomes of ¹⁷⁷Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.

Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Barber TW, et al. J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25. J Nucl Med. 2019. PMID: 30683770 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

228 results

Results by year